We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On May 11, 2010, the U.S. Food and Drug Administration (FDA) launched a new initiative the “Bad Ad Program” designed to educate health care practitioners about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading
On July 30, 2008, the House of Representatives approved by a 326 to 102 vote an amended version of H.R. 1108, the “Family Smoking Prevention and Tobacco Control Act,” which would give the FDA the authority to regulate tobacco products
The Food and Drug Administration (FDA) is announcing an opportunity for public comment on a planned FDA study examining consumer comprehension of inclusion of a toll-free number to report side effects in direct-to-consumer (DTC) prescription drug television advertisements
